Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma

Area of Science:

• Oncology
• Medicinal Chemistry
• Neuro-oncology

Background:

• CDK4 and CDK6 are key regulators of cell cycle progression and validated cancer targets.
• Glioblastoma frequently exhibits dysregulation of the CDKN2A/CCND2/CDK4/CDK6 pathway.
• Existing CDK4/6 inhibitors (abemaciclib, ribociclib, palbociclib) have poor blood-brain barrier penetration, limiting their use in brain tumors.

Purpose of the Study:

• To identify and characterize a brain-penetrant CDK4/6 inhibitor for glioblastoma therapy.
• To overcome the blood-brain barrier penetration limitations of current CDK4/6 inhibitors.

Main Methods:

• Modification of a literature molecule to improve blood-brain barrier penetration and CDK selectivity.
• Introduction of basic amines via pyrazole cyclization.
• In vivo assessment of brain penetration (mouse Kp,uu) and in vitro evaluation of potency and selectivity in glioblastoma cell lines.

Main Results:

• A brain-penetrant spiroazetidine inhibitor (cpKa = 8.8) was identified with good selectivity over CDK1.
• The lead compound demonstrated in vivo brain penetration (mouse Kp,uu = 0.20-0.59).
• Potency comparable to abemaciclib was observed in Rb-wild type glioblastoma cell lines (U87MG, DBTRG-05MG, A172, T98G).

Conclusions:

• A novel, brain-penetrant CDK4/6 inhibitor was successfully developed, showing promise for glioblastoma treatment.
• The compound's efficacy was dependent on Rb status, with sensitivity observed in Rb-wild type lines.
• This inhibitor represents a potential therapeutic strategy for glioblastoma by targeting the CDK4/6 pathway effectively within the brain.